Clinical trials: Ophthalmic Solutions
Allergic Conjunctivitis
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
- Trial name
- NCT01119287
- Testing
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease
The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group…
- Trial name
- HL_TSPR_302 (NCT02229955)
- Testing
- Cyclosporine ophthalmic solution
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Neuropathic Corneal Pain
Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).
This study is testing a new investigational study drug called Urcosimod Ophthalmic Solution for the treatment of Neuropathic Corneal Pain (NCP).
- Trial name
- NEPTUNE (NCT07838506)
- Testing
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Okyo Pharma Ltd
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Inflammation, Cataract
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.
- Trial name
- PRO-155 (NCT01535443)
- Testing
- Bromfenac
- Where
- Mexico
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ocular Itching, Ocular Allergy
Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118 ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal (SAC) and perennial (PAC) allergic…
- Conditions
- Ocular Itching, Ocular Allergy, Seasonal Allergic Conjunctivitis, Perennial Allergic Conjunctivitis
- Trial name
- PRO-118 (NCT01541904)
- Testing
- PRO-118 Ophthalmic Solution 0.015%, PRO-118 Ophthalmic Solution 0.015 %, PRO-118 Ophthalmic Solution 0.020 %
- Where
- 2 sites in Mexico
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndrome (DES)
Evaluation of a Novel Ocular Lubricating Eye Drop
The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.
- Trial name
- DRAGON (NCT07593404)
- Testing
- Part 2 ABR2 At least twice a day for 28 days, Part 1: ABR2 single dose in one eye
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pleryon Therapeutics (Hangzhou) Limited
Dry Eye Disease
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with Placebo when applied topically in subjects with dry eye disease.
- Trial name
- NCT00403715
- Testing
- diquafosol tetrasodium (INS365) Ophthalmic Solution
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Corneal Neovascularization
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
A Phase 1 randomized, double blinded, placebo-controlled, single dose escalation (SDE) and repeat dose escalation (RDE) study to evaluate safety and tolerability, and PK of KDR2-2 in healthy volunteers.
- Trial name
- NCT04620109
- Testing
- KDR2-2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Safety Study
A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults
The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group.
- Trial name
- NCT07370584
- Testing
- IVMED-85 ophthalmic solution, Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- iVeena Delivery Systems, Inc.
Glaucoma
A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.
- Trial name
- NCT00972426
- Testing
- carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Myopia, Astigmatism
Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers
The purpose of this study was to assess the comfort of OPTI-FREE RepleniSH in soft contact lens wearers.
- Conditions
- Myopia, Astigmatism, Refractive Error
- Trial name
- NCT01211535
- Testing
- OPTI-FREE RepleniSH multipurpose solution, ReNu Biotrue multipurpose solution, Silicone hydrogel contact lenses
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Phase 1 Study for Safety and Tolerability of HL036
To evaluate the safety, local tolerability and pharmacokinetic characteristics after administration of eye-drop HL036 in healthy Korean male volunteers
- Trial name
- NCT02717208
- Testing
- HL036, Vehicle
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973305
- Testing
- Dorzol 20 mg/ml, Trusopt 20 mg/ml
- Where
- Russia
- Volunteers
- 118 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Myopia
Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry.
- Trial name
- NCT07522242
- Testing
- T10430 lower dose, T10430 middle dose, T10430 higher dose
- Where
- 10 sites in Jordan, South Africa and 1 more
- Volunteers
- 200 people
- Sponsor
- Laboratoires Thea
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Non-Infectious Anterior Uveitis
Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis
The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are: 1.
- Trial name
- NCT07869953
- Testing
- Oftac: 0.05% tacrolimus ophthalmic emulsion
- Where
- 7 sites in Israel
- Volunteers
- 18 people
- Sponsor
- BioNanoSim Ltd.
Blepharoptosis
A Study in Chinese Patients With Acquired Blepharoptosis
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
- Trial name
- NCT06683651
- Testing
- STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800
- Where
- 23 sites in China
- Volunteers
- 180 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.